Clinical Trial

Testing Experimental Treatment for Frontotemporal Dementia

Study Description

A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients

A Phase 2 open label study evaluating the safety, tolerability, PK and PD of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.


Locations Selected Location


Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - AL001

administered via intravenous (IV) infusion once a month

Additional Information

Official Study Title

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia

Clinical Trial ID


ParticipAid ID